1Fibrinolytic Therapy Trialists Collaborative Group.Indications for fibrinolytic therapy in suspected acute myocardial infarction:collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients[J].Lancet,1994,343(8893):311-312.
4Cannon CP,Antman EM,Walls R,et al.Time as an adjunctive agent to thrombolytic therapy[J].Thromb Thrombolysis,1994,1(1):27-34.
5Boresma E,Maas AC,Deckers JW,et al.Early thrombolytic trestment in acute myocardialinfarction:reappraisal of the golden hour[J].Lancet,1996,348(9030):771-715.
6Bode C,Smalling RW,Berg G,et al.Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded,accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction.The RAPID Ⅱ Investigators[J].Circulation,1996,94(5):891-898.
8The INJECT Investigators.International Joint Efficacy Comparison of Thrombolytics.Randomised,double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT):trial to investigate equivalence[J].Lancet,1995,346(8971):329-336.
4The collaborative study group for national multicenter clinical trial of urokinase thrombolytic therapy (Correspondence: Hu Dayi, Xu Zhimin. Beijing Red Cross Chao Yao Hospital, Beijing 100020).尿激酶治疗急性心肌梗塞多中心临床试验1406例总结[J].中华心血管病杂志,1997,25(3):176-179. 被引量：138
